Exelixis Inc (EXEL) 13.64 $EXEL
Forget Novavax, Buy These 4 Biotech Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 2:50PM CDT
Shares of Novavax, Inc. (NVAX) plunged around 82% in pre-market trading on Friday after the biopharmaceutical company announced a day before that its key vaccine candidate unexpectedly failed to meet the primary endpoint in a phase III trial.
QLTI: 1.55 (-0.03), MON: 101.80 (-1.65), PFE: 33.65 (-0.29), VNDA: 15.20 (-0.35), MYL: 41.49 (-0.30), AEGR: 1.86 (+0.08), PDLI: 3.29 (+0.12), MDVN: 80.90 (+0.03), RPTP: 8.96 (-0.03), S: 6.65 (unch), NVAX: 1.49 (+0.20), HZNP: 19.12 (-0.16), EXEL: 13.64 (+0.09)
Will Exelixis (EXEL) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 10:11AM CDT
As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL)
EXEL: 13.64 (+0.09)
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
BusinessWire - Wed Sep 14, 12:00AM CDT
--- Approval of CABOMETYX in European Union triggers $60 million milestone payment to Exelixis under licensing agreement with Ipsen -
EXEL: 13.64 (+0.09)
Exelixis Reports Interim Analysis of Liver Cancer Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 2:44PM CDT
Exelixis, Inc. (EXEL) announced the outcome from the first planned interim analysis of a randomized phase III trial, CELESTIAL, on cabozantinib.
ANIP: 63.75 (-0.55), PCRX: 41.11 (-1.22), EXEL: 13.64 (+0.09)
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma
BusinessWire - Tue Sep 06, 4:08PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced the outcome from the first planned interim analysis of CELESTIAL, a randomized global phase 3 trial of cabozantinib compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Following this interim analysis, which was scheduled to take place when 50 percent of the events for the primary endpoint of overall survival (OS) had occurred, the trial's Independent Data Monitoring Committee (IDMC) determined that the study should continue without modifications per the study protocol. The trial protocol calls for a second interim analysis to take place once 75 percent of events have been observed.
EXEL: 13.64 (+0.09)
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
BusinessWire - Wed Aug 31, 3:17PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 12-14 in New York, NY. The Exelixis presentation is scheduled for 9:10 AM EDT/6:10 AM PDT on Tuesday, September 13, 2016.
EXEL: 13.64 (+0.09), MS: 31.60 (+0.01)
Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress
BusinessWire - Wed Aug 31, 7:30AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, October 7 - 11, 2016.
EXEL: 13.64 (+0.09)
Kinder Morgan trade offers a 6% return in 108 days, or find similar option trades on Amazon.com, Alleghany Technologies, Boeing, and Exelixis
PR Newswire - Tue Aug 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, ATI, BA, EXEL, and KMI.
KMI: 21.90 (+0.43), AMZN: 775.10 (-3.42), ATI: 16.32 (+0.55), BA: 127.48 (+0.78), EXEL: 13.64 (+0.09)
Why Exelixis (EXEL) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:00AM CDT
Exelixis (EXEL) has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front too.
EXEL: 13.64 (+0.09)
Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
BusinessWire - Wed Aug 24, 7:30AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has called for redemption approximately $48.1 million of its 4.25% Convertible Senior Subordinated Notes due 2019, representing all remaining notes outstanding. The redemption will be made in accordance with the terms of the indenture governing the notes and the terms of the redemption notice.
EXEL: 13.64 (+0.09)
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Acacia Communications, Radius Health, General Electric and Exelixis or any stock you choose
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACIA, EXEL, GE, RDUS, and VRX.
RDUS: 55.11 (-0.01), VRX: 27.10 (-0.18), GE: 29.43 (-0.25), ACIA: 114.26 (+1.44), EXEL: 13.64 (+0.09)
Covered Call reports for Valeant Pharmaceuticals, Merrimack Pharmaceuticals, Exelixis, Under Armour and Harman International Industries include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, HAR, MACK, UA, and VRX.
MACK: 4.61 (-0.08), UA: 38.74 (-0.17), VRX: 27.10 (-0.18), HAR: 81.81 (+0.25), EXEL: 13.64 (+0.09)
Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:52PM CDT
Exelixis, Inc. (EXEL) posted a second-quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of 27 cents and the year-ago loss of 22 cents
BIIB: 303.50 (-1.01), EXEL: 13.64 (+0.09)
Look for Shares of Exelixis to Potentially Pullback after Yesterday's 20.45% Rise
Comtex SmarTrend(R) - Thu Aug 04, 12:20PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $10.02 to a high of $11.66. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $9.40 on volume of 15.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 13.64 (+0.09)
Correction: Earns-Exelixis story
AP - Thu Aug 04, 10:16AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) — In a story August 4 about Exelixis Inc.'s quarterly results — generated by Automated Insights using data from Zacks Investment Research — The Associated Press reported erroneously that the company is forecasting annual revenue of $250 million to $270 million. Exelixis projects full-year operating expenses of $250 million to $270 million.
EXEL: 13.64 (+0.09)
Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
BusinessWire - Wed Aug 03, 3:17PM CDT
--- Conference Call and Webcast Today at 5:00 PM Eastern Time -
EXEL: 13.64 (+0.09)
Parker-Hannifin (PH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:33PM CDT
Leading manufacturer of motion & control technologies and systems, Parker-Hannifin Corporation (PH), is slated to report fourth-quarter fiscal 2016 results on Aug 4, before the opening bell.
HSC: 8.69 (-0.38), IPXL: 26.18 (+0.03), PH: 122.39 (+0.87), EXEL: 13.64 (+0.09)
Exelixis Shares Up 83.5% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Tue Aug 02, 12:41PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 3 months, Exelixis has returned 83.54% as of today's recent price of $9.03.
EXEL: 13.64 (+0.09)
Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:26AM CDT
GW Pharmaceuticals (GWPH), which is is set to report third-quarter fiscal 2016 results on Aug 4, had posted a positive surprise of 35.67% last quarter.
BMRN: 98.11 (+1.25), GWPH: 105.41 (+0.29), ICPT: 156.74 (-0.46), EXEL: 13.64 (+0.09)
Forget Novavax, Buy These 4 Biotech Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 2:50PM CDT
Shares of Novavax, Inc. (NVAX) plunged around 82% in pre-market trading on Friday after the biopharmaceutical company announced a day before that its key vaccine candidate unexpectedly failed to meet the primary endpoint in a phase III trial.
QLTI: 1.55 (-0.03), MON: 101.80 (-1.65), PFE: 33.65 (-0.29), VNDA: 15.20 (-0.35), MYL: 41.49 (-0.30), AEGR: 1.86 (+0.08), PDLI: 3.29 (+0.12), MDVN: 80.90 (+0.03), RPTP: 8.96 (-0.03), S: 6.65 (unch), NVAX: 1.49 (+0.20), HZNP: 19.12 (-0.16), EXEL: 13.64 (+0.09)
Will Exelixis (EXEL) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 10:11AM CDT
As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL)
EXEL: 13.64 (+0.09)
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
BusinessWire - Wed Sep 14, 12:00AM CDT
--- Approval of CABOMETYX in European Union triggers $60 million milestone payment to Exelixis under licensing agreement with Ipsen -
EXEL: 13.64 (+0.09)
Exelixis Reports Interim Analysis of Liver Cancer Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 2:44PM CDT
Exelixis, Inc. (EXEL) announced the outcome from the first planned interim analysis of a randomized phase III trial, CELESTIAL, on cabozantinib.
ANIP: 63.75 (-0.55), PCRX: 41.11 (-1.22), EXEL: 13.64 (+0.09)
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma
BusinessWire - Tue Sep 06, 4:08PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced the outcome from the first planned interim analysis of CELESTIAL, a randomized global phase 3 trial of cabozantinib compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Following this interim analysis, which was scheduled to take place when 50 percent of the events for the primary endpoint of overall survival (OS) had occurred, the trial's Independent Data Monitoring Committee (IDMC) determined that the study should continue without modifications per the study protocol. The trial protocol calls for a second interim analysis to take place once 75 percent of events have been observed.
EXEL: 13.64 (+0.09)
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
BusinessWire - Wed Aug 31, 3:17PM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 12-14 in New York, NY. The Exelixis presentation is scheduled for 9:10 AM EDT/6:10 AM PDT on Tuesday, September 13, 2016.
EXEL: 13.64 (+0.09), MS: 31.60 (+0.01)
Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress
BusinessWire - Wed Aug 31, 7:30AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of 15 presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, October 7 - 11, 2016.
EXEL: 13.64 (+0.09)
Kinder Morgan trade offers a 6% return in 108 days, or find similar option trades on Amazon.com, Alleghany Technologies, Boeing, and Exelixis
PR Newswire - Tue Aug 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, ATI, BA, EXEL, and KMI.
KMI: 21.90 (+0.43), AMZN: 775.10 (-3.42), ATI: 16.32 (+0.55), BA: 127.48 (+0.78), EXEL: 13.64 (+0.09)
Why Exelixis (EXEL) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:00AM CDT
Exelixis (EXEL) has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front too.
EXEL: 13.64 (+0.09)
Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
BusinessWire - Wed Aug 24, 7:30AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has called for redemption approximately $48.1 million of its 4.25% Convertible Senior Subordinated Notes due 2019, representing all remaining notes outstanding. The redemption will be made in accordance with the terms of the indenture governing the notes and the terms of the redemption notice.
EXEL: 13.64 (+0.09)
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Acacia Communications, Radius Health, General Electric and Exelixis or any stock you choose
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACIA, EXEL, GE, RDUS, and VRX.
RDUS: 55.11 (-0.01), VRX: 27.10 (-0.18), GE: 29.43 (-0.25), ACIA: 114.26 (+1.44), EXEL: 13.64 (+0.09)
Covered Call reports for Valeant Pharmaceuticals, Merrimack Pharmaceuticals, Exelixis, Under Armour and Harman International Industries include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, HAR, MACK, UA, and VRX.
MACK: 4.61 (-0.08), UA: 38.74 (-0.17), VRX: 27.10 (-0.18), HAR: 81.81 (+0.25), EXEL: 13.64 (+0.09)
Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:52PM CDT
Exelixis, Inc. (EXEL) posted a second-quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of 27 cents and the year-ago loss of 22 cents
BIIB: 303.50 (-1.01), EXEL: 13.64 (+0.09)
Look for Shares of Exelixis to Potentially Pullback after Yesterday's 20.45% Rise
Comtex SmarTrend(R) - Thu Aug 04, 12:20PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $10.02 to a high of $11.66. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $9.40 on volume of 15.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 13.64 (+0.09)
Correction: Earns-Exelixis story
AP - Thu Aug 04, 10:16AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) — In a story August 4 about Exelixis Inc.'s quarterly results — generated by Automated Insights using data from Zacks Investment Research — The Associated Press reported erroneously that the company is forecasting annual revenue of $250 million to $270 million. Exelixis projects full-year operating expenses of $250 million to $270 million.
EXEL: 13.64 (+0.09)
Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
BusinessWire - Wed Aug 03, 3:17PM CDT
--- Conference Call and Webcast Today at 5:00 PM Eastern Time -
EXEL: 13.64 (+0.09)
Parker-Hannifin (PH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 5:33PM CDT
Leading manufacturer of motion & control technologies and systems, Parker-Hannifin Corporation (PH), is slated to report fourth-quarter fiscal 2016 results on Aug 4, before the opening bell.
HSC: 8.69 (-0.38), IPXL: 26.18 (+0.03), PH: 122.39 (+0.87), EXEL: 13.64 (+0.09)
Exelixis Shares Up 83.5% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Tue Aug 02, 12:41PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 3 months, Exelixis has returned 83.54% as of today's recent price of $9.03.
EXEL: 13.64 (+0.09)
Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:26AM CDT
GW Pharmaceuticals (GWPH), which is is set to report third-quarter fiscal 2016 results on Aug 4, had posted a positive surprise of 35.67% last quarter.
BMRN: 98.11 (+1.25), GWPH: 105.41 (+0.29), ICPT: 156.74 (-0.46), EXEL: 13.64 (+0.09)
